For Immediate Release March 23, 2021

Montreal, Quebec, Canada — (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of  $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with  RB Capital Partners Inc. The financing is in the form of fixed-price convertible debt which now  stands at a weighted average conversion price of $0.43 per share. This debt is obligatorily convertible on or before the maturity date. 

The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. Development of both projects is currently underway and the research is progressing as planned. On February 1, 2021, Sunshine Biopharma initiated a transgenic mice study for two Anti-Coronavirus compounds in collaboration with the University of Georgia. The goal of the ongoing study is to determine if these protease inhibitors will protect  the hACE2-transgenic mice from progression to disease and death following infection with SARS 

CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19  patient volunteers in a Phase I clinical trial setting. 

Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We continue to push ahead with the development of our COVID-19 treatment in collaboration with the University of Georgia and our  Adva-27a anticancer compound with our corporate partners in Montreal. This investment is integral to our progress in both of these crucial drug development sectors.” 

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 2.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest the replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus  PLpro protease, thus shutting down the ability of the virus to multiply. PLpro is present only in the SARS  Coronaviruses (Betacoronaviruses) and is an important antiviral target as it is involved in shutting down the host’s innate immune system. On February 1, 2021, Sunshine Biopharma entered into an exclusive license  agreement with the University of Georgia for two additional Anti-Coronavirus compounds which the 

The University of Georgia had previously developed and patented. Sunshine Biopharma is currently advancing the development of these two compounds in parallel with the Company’s own (SBFM-PL4) by conducting a transgenic mice study in collaboration with the University of Georgia. The goal of the ongoing study is to determine if our protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine  Biopharma plans to submit the results to the FDA and Health Canada for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. 

About Sunshine Biopharma’s Anticancer Compound 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464